Patents by Inventor Kerstin Wunderlich

Kerstin Wunderlich has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Potent and balanced bidirectional promoter
    Patent number: 11781155
    Abstract: The invention provides a bidirectional hCMV-rhCMV promoter and recombinant vectors and recombinant virus comprising the bidirectional hCMV-rhCMV promoter operably linked to a first transgene in one direction and to a second transgene in the opposite direction. The invention also provides methods of making and using such recombinant vectors and recombinant virus.
    Type: Grant
    Filed: March 17, 2021
    Date of Patent: October 10, 2023
    Assignee: Janssen Vaccines & Prevention B.V.
    Inventors: Kerstin Wunderlich, Jort Vellinga
  • POTENT AND BALANCED BIDIRECTIONAL PROMOTER
    Publication number: 20230279425
    Abstract: The invention provides a bidirectional hCMV-CAG4 promoter and recombinant vectors and recombinant virus comprising the bidirectional hCMV-CAG4 promoter operably linked to a first transgene in one direction and to a second transgene in the opposite direction. The invention also provides methods of making and using such recombinant vectors and recombinant virus.
    Type: Application
    Filed: September 7, 2022
    Publication date: September 7, 2023
    Inventors: Kerstin WUNDERLICH, Jort VELLINGA
  • Potent and balanced bidirectional promoter
    Patent number: 11473105
    Abstract: The invention provides a bidirectional hCMV-CAG4 promoter and recombinant vectors and recombinant virus comprising the bidirectional hCMV-CAG4 promoter operably linked to a first transgene in one direction and to a second transgene in the opposite direction. The invention also provides methods of making and using such recombinant vectors and recombinant virus.
    Type: Grant
    Filed: May 11, 2017
    Date of Patent: October 18, 2022
    Assignee: Janssen Vaccines & Prevention B.V.
    Inventors: Kerstin Wunderlich, Jort Vellinga
  • POTENT AND SHORT PROMOTER FOR EXPRESSION OF HETEROLOGOUS GENES
    Publication number: 20210261984
    Abstract: The invention provides an AoHV-1 promoter for use with plasmid vectors, viral vectors, viruses, and cell lines comprising the AoHV-1 promoter operably linked to a transgene. The invention also provides methods of making and using recombinant plasmid vectors, viral vectors, viruses, and cell lines comprising the AoHV-1 promoter operably linked to a transgene.
    Type: Application
    Filed: May 7, 2021
    Publication date: August 26, 2021
    Inventors: Kerstin WUNDERLICH, Taco Gilles UIL, Jort VELLINGA, Barbara Petronella SANDERS, Remko VAN DER VLUGT
  • Potent and short promoter for expression of heterologous genes
    Patent number: 11034978
    Abstract: The invention provides an AoHV-1 promoter for use with plasmid vectors, viral vectors, viruses, and cell lines comprising the AoHV-1 promoter operably linked to a transgene. The invention also provides methods of making and using recombinant plasmid vectors, viral vectors, viruses, and cell lines comprising the AoHV-1 promoter operably linked to a transgene.
    Type: Grant
    Filed: February 8, 2018
    Date of Patent: June 15, 2021
    Assignee: Janssen Vaccines & Prevention B.V.
    Inventors: Kerstin Wunderlich, Taco Gilles Uil, Jort Vellinga, Barbara Petronella Sanders, Remko Van Der Vlugt
  • Potent and balanced bidirectional promoter
    Patent number: 11001858
    Abstract: The invention provides a bidirectional hCMV-rhCMV promoter and recombinant vectors and recombinant virus comprising the bidirectional hCMV-rhCMV promoter operably linked to a first transgene in one direction and to a second transgene in the opposite direction. The invention also provides methods of making and using such recombinant vectors and recombinant virus.
    Type: Grant
    Filed: June 19, 2017
    Date of Patent: May 11, 2021
    Assignee: Janssen Vaccines & Prevention B.V.
    Inventors: Kerstin Wunderlich, Jort Vellinga
  • Recombinant adenovirus expressing two transgenes with a bidirectional promoter
    Patent number: 10570417
    Abstract: The invention provides recombinant adenovirus (rAd) and rAd vectors comprising a bidirectional mouse CMV (mCMV) promoter operably linked to a first transgene in one direction and to a second transgene in the opposite direction. The invention also provides methods of making and using such rAd and rAd vectors.
    Type: Grant
    Filed: April 12, 2016
    Date of Patent: February 25, 2020
    Assignee: Janssen Vaccines & Prevention B.V.
    Inventors: Kerstin Wunderlich, Jerôme H. H. V. Custers, Jort Vellinga, Barbara Petronella Sanders
  • POTENT AND BALANCED BIDIRECTIONAL PROMOTER
    Publication number: 20190264225
    Abstract: The invention provides a bidirectional hCMV-CAG4 promoter and recombinant vectors and recombinant virus comprising the bidirectional hCMV-CAG4 promoter operably linked to a first transgene in one direction and to a second transgene in the opposite direction. The invention also provides methods of making and using such recombinant vectors and recombinant virus.
    Type: Application
    Filed: May 11, 2017
    Publication date: August 29, 2019
    Applicant: Janseen Vacines & Prevention B.V.
    Inventors: Kerstin WUNDERLICH, Jort VELLINGA
  • POTENT AND BALANCED BIDIRECTIONAL PROMOTER
    Publication number: 20190225987
    Abstract: The invention provides a bidirectional hCMV-rhCMV promoter and recombinant vectors and recombinant virus comprising the bidirectional hCMV-rhCMV promoter operably linked to a first transgene in one direction and to a second transgene in the opposite direction. The invention also provides methods of making and using such recombinant vectors and recombinant virus.
    Type: Application
    Filed: June 19, 2017
    Publication date: July 25, 2019
    Inventors: Kerstin WUNDERLICH, Jort VELLINGA
  • POTENT AND SHORT PROMOTER FOR EXPRESSION OF HETEROLOGOUS GENES
    Publication number: 20180223314
    Abstract: The invention provides an AoHV-1 promoter for use with plasmid vectors, viral vectors, viruses, and cell lines comprising the AoHV-1 promoter operably linked to a transgene. The invention also provides methods of making and using recombinant plasmid vectors, viral vectors, viruses, and cell lines comprising the AoHV-1 promoter operably linked to a transgene.
    Type: Application
    Filed: February 8, 2018
    Publication date: August 9, 2018
    Inventors: Kerstin WUNDERLICH, Taco Gilles UIL, Jort VELLINGA, Barbara Petronella SANDERS, Remko VAN DER VLUGT
  • RECOMBINANT ADENOVIRUS EXPRESSING TWO TRANSGENES WITH A BIDIRECTIONAL PROMOTER
    Publication number: 20180135075
    Abstract: The invention provides recombinant adenovirus (rAd) and rAd vectors comprising a bidirectional mouse CMV (mCMV) promoter operably linked to a first transgene in one direction and to a second transgene in the opposite direction. The invention also provides methods of making and using such rAd and rAd vectors.
    Type: Application
    Filed: April 12, 2016
    Publication date: May 17, 2018
    Inventors: Kerstin WUNDERLICH, Jerôme H.H.V. CUSTERS, Jort VELLINGA, Barbara Petronella SANDERS
  • INFLUENZA A AND B VIRUS REPLICATION-INHIBITING PEPTIDES
    Publication number: 20120129764
    Abstract: A synthesized or isolated influenza virus replication-inhibiting peptide that competitively inhibits protein-protein interaction of the PA and PB1 of both influenza Virus Types A and B and novel in vitro binding screen to identify peptides with antiviral activity against influenza viruses of both type A and B is disclosed. In addition to the well-known pandemic influenza A viruses (such as the 1918 “Spanish” flu or H5N1), both type A and B viruses contribute greatly to the annual recurring epidemics that cause the vast majority of human cases and medical cost. Surprisingly, it was found that the novel virus replication-inhibiting, are able to inhibit protein-protein interaction of the PA and PB1 subunits of the heterotrimeric viral RNA polymerase complex of both influenza virus types A and B.
    Type: Application
    Filed: May 8, 2009
    Publication date: May 24, 2012
    Applicant: PIKE PHARMA GMBH
    Inventors: Ulrich Kessler, Daniel Mayer, Kerstin Wunderlich, Charlene Rnadheera, Martin Schwemmle